Experimental Alzheimer’s drug stirs hope after early trials

Local
Alzheimer's experimental drug 07.26.18_1532620549936.PNG.jpg

After a series of prominent failures, there’s reason to be hopeful in the search for a drug to slow the progression of Alzheimer’s disease.

Results of an early trial of an experimental drug showed that it improved cognition and reduced clinical signs of Alzheimer’s in the brains of study participants, and experts are “cautiously optimistic” that the results will be duplicated in future clinical trials.

The drug, an antibody called BAN2401, not only reduced the formulation of new beta amyloid clusters in the brain, it reduced existing clusters by 70% on average, American biotechnology company Biogen and Japanese drugmaker Eisai announced Wednesday.

Click here for more 

Copyright 2021 Nexstar Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Loving Living Local 600x600

Don't Miss